Based on our preclinical study, ERK pathway inhibitors, PD-L1/PD-1 inhibitors or combination strategies should be considered to overcome the TKI resistance and improve outcomes in NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.